Impact_NN of_IN false-positive_JJ mammography_NN on_IN subsequent_JJ screening_NN attendance_NN and_CC risk_NN of_IN cancer_NN Abstract_NP |_SYM Background_NP |_SYM One_CD area_NN of_IN concern_NN within_IN the_DT largely_RB successful_JJ UK_NP National_NP Health_NP Service_NP breast_NN screening_NN programme_NN is_VBZ the_DT relatively_RB high_JJ proportion_NN of_IN women_NNS showing_VBG mammographic_JJ abnormalities_NNS who_WP undergo_VBP further_RBR diagnostic_JJ tests_NNS that_WDT prove_VBP negative_JJ ._SENT Previous_JJ studies_NNS suggest_VBP that_IN ,_, in_IN addition_NN to_TO increasing_VBG anxiety_NN ,_, such_JJ false-positive_JJ mammography_NN is_VBZ associated_VBN with_IN increased_VBN risk_NN of_IN subsequent_JJ interval_NN cancer_NN ._SENT In_IN the_DT present_JJ article_NN ,_, we_PP quantify_VBP this_DT increased_VBN risk_NN ,_, investigate_VB whether_IN it_PP extends_VBZ to_TO cancers_NNS detected_VBN at_IN rescreening_NN ,_, and_CC determine_VB whether_IN cancers_NNS differ_VBP between_IN women_NNS who_WP have_VBP ,_, and_CC have_VBP not_RB ,_, experienced_JJ false-positive_JJ mammography_NN ._SENT Methods_NNS |_SYM This_DT was_VBD a_DT retrospective_JJ cohort_NN study_NN of_IN 140,387_CD women_NNS aged_VBN 49_CD --_: 63_CD years_NNS routinely_RB invited_VBN for_IN first_JJ screening_NN by_IN the_DT East_NP Anglian_JJ National_NP Health_NP Service_NP breast_NN screening_NN programme_NN ._SENT Proportions_NNS reattending_NN ,_, and_CC subsequent_JJ risk_NN and_CC pathological_JJ attributes_NNS of_IN cancer_NN were_VBD compared_VBN between_IN women_NNS who_WP underwent_VBD further_RBR (_( negative_JJ )_) assessment_NN following_VBG false-positive_JJ mammography_NN and_CC women_NNS mammographically_RB normal_JJ at_IN first_JJ screen_NN ._SENT Results_NNS |_SYM At_IN first_JJ screen_NN ,_, 108,617_CD (_( 91.9_CD %_NN )_) of_IN the_DT screened_VBN women_NNS were_VBD mammographically_RB normal_JJ ,_, 4278_CD (_( 3.6_CD %_NN )_) were_VBD assessed_VBN and_CC then_RB judged_VBN normal_JJ ,_, and_CC 514_CD (_( 0.4_CD %_NN )_) underwent_VBD benign_JJ biopsy_NN ._SENT Compared_VBN with_IN nonassessed_JJ normal_JJ women_NNS ,_, reattendance_NN was_VBD lower_JJR among_IN assessed_VBN women_NNS :_: 83.1_CD %_NN (_( 95_CD %_NN confidence_NN interval_NN [_SYM CI_NP ]_SYM ,_, 82.0_CD --_: 84.1_LS )_) versus_CC 85.7_CD %_NN (_( 95_CD %_NN CI_NP ,_, 85.5_CD --_: 85.9_LS )_) (_( odds_NNS ratio_NN [_SYM OR_NP ]_SYM ,_, 0.82_CD ;_: 95_CD %_NN CI_NP ,_, 0.76_CD --_: 0.89_CD )_) ._SENT Assessed_VBN women_NNS were_VBD at_IN greater_JJR risk_NN of_IN interval_NN cancer_NN (_( rate_NN per_IN 1000_CD women_NNS screened_VBD ,_, 9.6_CD [_SYM 95_CD %_NN CI_NP ,_, 6.8_CD --_: 12.4_CD ]_SYM versus_FW 3.0_CD [_SYM 95_CD %_NN CI_NP ,_, 2.7_CD --_: 3.4_CD ]_SYM ;_: OR_JJ ,_, 3.19_CD [_SYM 95_CD %_NN CI_NP ,_, 2.34_CD --_: 4.35_CD ]_SYM )_) ,_, and_CC also_RB of_IN cancer_NN detected_VBN at_IN second_JJ screen_NN (_( rate_NN per_IN 1000_CD ,_, 8.4_CD [_SYM 95_CD %_NN CI_NP ,_, 5.8_CD --_: 10.9_CD ]_SYM versus_FW 3.9_CD [_SYM 95_CD %_NN CI_NP ,_, 3.5_CD --_: 4.3_CD ]_SYM ;_: OR_JJ ,_, 2.15_CD [_SYM 95_CD %_NN CI_NP ,_, 1.55_CD --_: 2.98_CD ]_SYM )_) ._SENT More_JJR cancers_NNS in_IN assessed_VBN women_NNS measured_VBN >=_NP 20_CD mm_NN (_( OR_NP ,_, 1.59_CD ;_: 95_CD %_NN CI_NP ,_, 0.99_CD --_: 2.55_CD )_) ._SENT Conclusions_NNS |_SYM Women_NNS undergoing_VBG false-positive_JJ mammography_NN at_IN first_JJ screen_NN were_VBD less_RBR likely_JJ to_TO reattend_VB for_IN subsequent_JJ screens_NNS than_IN were_VBD nonassessed_JJ women_NNS ,_, yet_RB they_PP were_VBD more_RBR likely_JJ to_TO develop_VB interval_NN cancers_NNS or_CC cancers_NNS at_IN second_JJ screen_NN ,_, and_CC their_PP$ cancers_NNS were_VBD larger_JJR ._SENT Factors_NNS predisposing_VBG for_IN false-positive_JJ mammography_NN require_VBP investigation_NN ._SENT Women_NNS should_MD be_VB encouraged_VBN to_TO continue_VB with_IN screening_NN ._SENT breast_NN screening_NN ,_, false-positive_JJ mammography_NN ,_, interval_NN cancer_NN ,_, screen-detected_JJ cancer_NN ,_, screening_VBG attendance_NN ,_, positive_JJ mammography_NN ,_, interval_NN cancer_NN ,_, screen-detected_JJ cancer_NN ,_, screening_VBG attendance_NN ,_, Introduction_NP :_: Effective_JJ population-based_JJ screening_NN requires_VBZ adequate_JJ compliance_NN among_IN the_DT target_NN population_NN ._SENT The_DT goal_NN of_IN the_DT UK_NP breast_NN screening_NN programme_NN ,_, a_DT 25_CD %_NN reduction_NN in_IN mortality_NN ,_, required_VBN first-screen_NN compliance_NN to_TO be_VB 70_CD %_NN ._SENT This_DT target_NN was_VBD exceeded_VBN in_IN many_JJ areas_NNS throughout_IN the_DT UK_NP ._SENT Another_DT key_JJ prerequisite_NN to_TO maintaining_VBG a_DT successful_JJ screening_NN programme_NN is_VBZ acceptability_NN ,_, and_CC the_DT >=_JJ 90_CD %_NN reattendance_NN rate_NN among_IN previous_JJ screenees_NNS indicated_VBD high_JJ acceptability_NN in_IN UK_NP women_NNS ._SENT Despite_IN meeting_VBG most_JJS of_IN the_DT targets_NNS set_VBP ,_, however_RB ,_, breast_NN screening_NN in_IN the_DT UK_NP has_VBZ not_RB been_VBN an_DT unmitigated_JJ success_NN story_NN ._SENT When_WRB screening_NN was_VBD introduced_VBN there_EX were_VBD reports_NNS of_IN increased_VBN anxiety_NN among_IN the_DT large_JJ numbers_NNS of_IN women_NNS undergoing_VBG assessment_NN following_VBG positive_JJ screening_NN mammography_NN ._SENT Although_IN most_JJS women_NNS do_VBP not_RB show_VB abnormalities_NNS on_IN their_PP$ screening_NN mammograms_NNS and_CC are_VBP simply_RB asked_VBN to_TO return_VB for_IN rescreening_NN in_IN 3_CD years_NNS ,_, the_DT mammograms_NNS of_IN 5_CD --_: 9_CD %_NN of_IN all_DT women_NNS indicate_VBP possible_JJ malignancy_NN ._SENT These_DT women_NNS must_MD undergo_VB a_DT second_NN '_POS assessment_NN '_POS phase_NN of_IN the_DT screening_NN process_NN ,_, which_WDT involves_VBZ further_JJR procedures_NNS such_JJ as_IN ultrasound_NN ,_, needle_NN biopsy_NN and_CC ,_, possibly_RB ,_, open_JJ biopsy_NN to_TO establish_VB a_DT definitive_JJ diagnosis_NN ._SENT As_IN expected_VBN ,_, malignancy_NN is_VBZ ruled_VBN out_RP for_IN the_DT majority_NN of_IN women_NNS assessed_VBD ,_, indicating_VBG that_IN the_DT result_NN of_IN their_PP$ mammography_NN was_VBD falsely_RB positive_JJ ._SENT In_IN the_DT current_JJ study_NN ,_, the_DT term_NN '_POS false_JJ positive_NN '_'' is_VBZ thus_RB applied_VBN to_TO any_DT woman_NN who_WP is_VBZ recalled_VBN for_IN assessment_NN on_IN the_DT basis_NN of_IN mammographic_JJ findings_NNS and_CC in_IN whom_WP cancer_NN is_VBZ not_RB diagnosed_VBN ._SENT Other_JJ studies_NNS may_MD limit_VB use_NN of_IN the_DT term_NN only_RB to_TO those_DT women_NNS who_WP have_VBP undergone_VBN open_JJ biopsy_NN with_IN no_DT resultant_JJ diagnosis_NN of_IN cancer_NN ._SENT Although_IN some_DT studies_NNS have_VBP indicated_VBN that_IN false-positive_JJ mammography_NN does_VBZ not_RB deter_VB women_NNS from_IN reattending_NN ,_, it_PP clearly_RB has_VBZ associated_VBN financial_JJ and_CC psychological_JJ costs_NNS ._SENT Furthermore_RB ,_, ourselves_PP and_CC other_JJ workers_NNS have_VBP found_VBN that_IN women_NNS judged_VBD false_JJ positive_NN at_IN first_JJ screen_NN are_VBP more_RBR likely_JJ to_TO develop_VB an_DT interval_NN cancer_NN before_IN the_DT second_JJ screening_NN is_VBZ due_JJ ._SENT To_TO assess_VB the_DT impact_NN of_IN false-positive_JJ mammography_NN on_IN screening_VBG effectiveness_NN ,_, we_PP investigate_VBP whether_IN false-positive_JJ mammography_NN affects_VBZ subsequent_JJ reattendance_NN in_IN East_NP Anglia_NP ._SENT We_PP quantify_VBP the_DT magnitude_NN of_IN the_DT increased_VBN risk_NN of_IN interval_NN cancer_NN ,_, and_CC extend_VB these_DT investigations_NNS to_TO determine_VB whether_IN false-positive_JJ mammography_NN at_IN first_JJ screen_NN increases_VBZ the_DT risk_NN of_IN cancer_NN detected_VBN at_IN second_JJ screen_NN ._SENT Finally_RB ,_, we_PP compare_VBP the_DT pathology_NN of_IN cancers_NNS presenting_VBG in_IN women_NNS who_WP have_VBP undergone_VBN false-positive_JJ mammography_NN with_IN that_DT of_IN cancers_NNS in_IN women_NNS judged_VBN normal_JJ at_IN the_DT preceding_JJ screening_NN ._SENT Screening_NN was_VBD introduced_VBN in_IN East_NP Anglia_NP over_IN the_DT period_NN 1989_CD --_: 1991_CD ._SENT Women_NNS were_VBD invited_VBN by_IN year_NN of_IN birth_NN ,_, in_IN 5-year_JJ age_NN groups_NNS ._SENT The_DT first_JJ round_NN of_IN screening_NN occurred_VBN in_IN 1989_CD --_: 1995_CD ,_, and_CC the_DT second_NN occurred_VBD 3_CD years_NNS later_RBR (_( 1992_LS --_: 1998_LS )_) ._SENT All_DT women_NNS invited_VBN to_TO the_DT first_JJ round_NN ,_, and_CC eligible_JJ for_IN reinvitation_NN to_TO the_DT second_JJ ,_, were_VBD identified_VBN on_IN the_DT breast_NN screening_NN computer_NN system_NN ._SENT The_DT majority_NN was_VBD aged_VBN 50_CD --_: 62_CD years_NNS ._SENT Those_DT aged_VBN 63_CD --_: 64_CD years_NNS were_VBD beyond_IN the_DT invited_VBN age_NN range_NN at_IN the_DT time_NN of_IN the_DT second_JJ screen_NN and_CC were_VBD excluded_VBN ._SENT We_PP only_RB included_VBD women_NNS invited_VBN on_IN schedule_NN (_( i.e._FW within_IN 24_CD months_NNS of_IN commencing_VBG invitation_NN of_IN the_DT relevant_JJ birth_NN cohort_NN )_) in_IN order_NN to_TO exclude_VB women_NNS who_WP failed_VBD to_TO respond_VB at_IN first_JJ invitation_NN but_CC who_WP attended_VBD for_IN the_DT first_JJ time_NN on_IN reinvitation_NN 3_CD years_NNS later_RBR ._SENT Women_NNS were_VBD followed_VBN up_RP from_IN the_DT date_NN of_IN first_JJ invitation_NN until_IN invitation_NN to_TO the_DT second_JJ screening_NN if_IN within_IN 3.5_CD years_NNS (_( i.e._FW 1277_CD days_NNS )_) ,_, or_CC for_IN the_DT mean_JJ interscreen_NN interval_NN for_IN the_DT screening_NN unit_NN if_IN no_DT screen_NN occurred_VBD within_IN this_DT time_NN (_( mean_VB +-_JJ standard_JJ error_NN interscreen_NN interval_NN for_IN all_DT regional_JJ screening_NN units_NNS ,_, 1106_CD +-_NN 7.6_CD days_NNS )_) ._SENT Interval_NN and_CC screen-detected_JJ cancers_NNS were_VBD identified_VBN by_IN matching_VBG screening_NN unit_NN and_CC Cancer_NP Registry_NP databases_NNS as_RB described_VBD previously_RB ._SENT Women_NNS not_RB attending_VBG within_IN 6_CD months_NNS of_IN the_DT first_JJ invitation_NN were_VBD deemed_VBN to_TO have_VB refused_VBN screening_NN ._SENT With_IN the_DT exception_NN of_IN women_NNS attending_VBG for_IN the_DT first_JJ invitation_NN within_IN 6_CD months_NNS but_CC placed_VBN on_IN early_JJ recall_NN ,_, only_RB those_DT women_NNS whose_WP$ second_JJ screening_NN episode_NN (_( either_CC accepted_VBN or_CC refused_VBN )_) was_VBD completed_VBN within_IN 3.5_CD years_NNS of_IN the_DT first_JJ invitation_NN are_VBP considered_VBN in_IN the_DT present_JJ analysis_NN ._SENT Information_NN on_IN prognostic_JJ characteristics_NNS size_NN (_( maximum_JJ diameter_NN of_IN invasive_JJ component_NN )_) ,_, grade_NN ,_, node_NN status_NN and_CC histological_JJ subtype_NN was_VBD obtained_VBN from_IN the_DT Cancer_NP Registry_NP ,_, from_IN screening_NN units_NNS and_CC from_IN medical_JJ records_NNS ._SENT Cancers_NNS were_VBD assigned_VBN a_DT prognostic_JJ risk_NN group_NN ,_, based_VBN on_IN histological_JJ type_NN and_CC malignancy_NN grade_NN ._SENT Differences_NNS in_IN distribution_NN of_IN these_DT attributes_NNS ,_, and_CC of_IN the_DT risk_NN of_IN cancer_NN ,_, among_IN study_NN groups_NNS were_VBD expressed_VBN as_IN ORs_NP ._SENT Table_NN presents_VBZ the_DT relationship_NN of_IN the_DT study_NN groups_NNS to_TO the_DT total_JJ population_NN of_IN 203,194_CD women_NNS eligible_JJ for_IN invitation_NN to_TO the_DT first_JJ screening_NN round_NN ._SENT Of_IN these_DT women_NNS ,_, 140,387_CD (_( 69.1_CD %_NN )_) were_VBD identified_VBN as_IN first-round_JJ invitees_NNS who_WP were_VBD invited_VBN within_IN schedule_NN and_CC were_VBD eligible_JJ for_IN reinvitation_NN to_TO rescreening_NN ._SENT Table_NP 1_CD |_SYM Relationship_NN of_IN study_NN groups_NNS to_TO total_VB population_NN of_IN women_NNS eligible_JJ for_IN and_CC invited_VBN to_TO the_DT first_JJ screening_NN round_NN in_IN East_NP Anglia_NP Of_IN these_DT 140,387_CD women_NNS ,_, 118,216_CD (_( 84.2_CD %_NN )_) completed_VBD a_DT satisfactory_JJ first_JJ screen_NN within_IN 6_CD months_NNS of_IN the_DT first_JJ appointment_NN ._SENT At_IN first_JJ appointment_NN ,_, 108,617_CD (_( 77.4_CD %_NN )_) were_VBD judged_VBN normal_JJ on_IN the_DT basis_NN of_IN mammography_NN alone_RB (_( the_NP '_POS non-assessed_JJ normal_NN '_POS group_NN )_) ._SENT Of_IN 6460_CD (_( 4.6_CD %_NN )_) women_NNS who_WP underwent_VBD further_JJR assessment_NN to_TO establish_VB definitive_JJ diagnosis_NN ,_, 6337_CD were_VBD investigated_VBN immediately_RB ;_: the_DT remainder_NN underwent_VBD further_JJR appointments_NNS for_IN technical_JJ reasons_NNS or_CC through_IN failure_NN to_TO respond_VB to_TO invitations_NNS ._SENT Of_IN those_DT assessed_VBN immediately_RB ,_, 4278_CD women_NNS were_VBD judged_VBN normal_JJ at_IN assessment_NN (_( '_POS assessed_VBN normal_NN '_POS group_NN )_) ,_, and_CC 514_CD proceeded_VBD to_TO open_VB biopsy_NN ,_, the_DT result_NN of_IN which_WDT was_VBD benign_JJ (_( '_POS assessed_VBN benign_JJ '_'' group_NN )_) ._SENT Women_NNS in_IN assessed_VBN normal_JJ and_CC assessed_VBN benign_JJ groups_NNS returned_VBD directly_RB to_TO routine_JJ screening_NN ._SENT Overall_RB ,_, there_EX were_VBD 113,409_CD women_NNS in_IN the_DT nonassessed_JJ normal_JJ ,_, assessed_VBD normal_JJ and_CC assessed_VBN benign_JJ study_NN groups_NNS ,_, comprising_VBG 80.8_CD %_NN of_IN all_DT women_NNS who_WP were_VBD invited_VBN for_IN a_DT routine_JJ first_JJ screen_NN within_IN schedule_NN and_CC were_VBD eligible_JJ for_IN reinvitation_NN to_TO the_DT second_JJ round_NN ._SENT The_DT mean_JJ +-_NN standard_JJ deviation_NN age_NN of_IN women_NNS was_VBD similar_JJ in_IN all_DT study_NN groups_NNS :_: 56.0_CD +-_NN 3.5_CD years_NNS in_IN the_DT entire_JJ invited_VBN cohort_NN eligible_NN for_IN reinvitation_NN ,_, 55.8_CD +-_NN 3.5_CD years_NNS in_IN the_DT nonassessed_JJ normal_JJ group_NN ,_, 56.1_CD +-_NN 3.5_CD years_NNS in_IN the_DT assessed_VBN normal_JJ group_NN ,_, and_CC 56.4_CD +-_NN 3.6_CD years_NNS in_IN the_DT assessed_VBN benign_JJ group_NN ._SENT Of_IN the_DT 6337_CD women_NNS assessed_VBN immediately_RB following_VBG the_DT first_JJ screen_NN ,_, 680_CD were_VBD initially_RB diagnosed_VBN with_IN cancer_NN ._SENT A_DT further_JJR 11_CD women_NNS were_VBD diagnosed_VBN following_VBG initial_JJ nonattendance_NN at_IN assessment_NN ,_, and_CC 22_CD at_IN early_JJ recall_NN ._SENT This_DT produced_VBD a_DT total_NN of_IN 713_CD women_NNS ._SENT Of_IN the_DT 680_CD women_NNS diagnosed_VBN at_IN initial_JJ assessment_NN ,_, 676_CD were_VBD registered_VBN at_IN the_DT Cancer_NP Registry_NP ._SENT The_DT remaining_VBG four_CD women_NNS were_VBD either_RB recurrences_NNS of_IN earlier_JJR breast_NN primaries_NNS or_CC other_JJ malignancies_NNS not_RB classified_VBN as_IN primary_JJ breast_NN cancer_NN (_( e.g._FW cytosarcoma_NN phyllodes_NNS )_) ._SENT Numbers_NNS of_IN cases_NNS ,_, rates_NNS per_IN 1000_CD screened_VBD ,_, and_CC odds_NNS of_IN presenting_VBG with_IN interval_NN cancer_NN or_CC having_VBG a_DT cancer_NN detected_VBN at_IN second_JJ screen_NN are_VBP presented_VBN by_IN study_NN group_NN in_IN Table_NP ._SENT In_IN all_DT study_NN groups_NNS combined_JJ ,_, 375_CD interval_NN cancers_NNS presented_VBD and_CC 463_CD cancers_NNS were_VBD detected_VBN at_IN second_JJ screen_NN ._SENT The_DT risk_NN of_IN subsequent_JJ interval_NN cancer_NN ,_, or_CC cancer_NN detected_VBN at_IN second_JJ screen_NN ,_, was_VBD higher_JJR in_IN women_NNS assessed_VBN at_IN the_DT preceding_JJ screen_NN ._SENT The_DT OR_NN among_IN all_DT assessed_VBN women_NNS for_IN an_DT interval_NN cancer_NN arising_VBG was_VBD 3.19_CD (_( 95_CD %_NN CI_NP ,_, 2.34_CD --_: 4.35_LS )_) compared_VBN with_IN the_DT nonassessed_JJ normal_JJ group_NN ,_, and_CC that_IN for_IN detecting_VBG a_DT cancer_NN at_IN second_JJ screen_NN was_VBD 2.15_CD (_( 95_CD %_NN CI_NP ,_, 1.55_CD --_: 2.98_CD )_) ._SENT Compared_VBN with_IN the_DT nonassessed_JJ normal_JJ group_NN ,_, the_DT OR_NN of_IN a_DT second_JJ round_NN screen-detected_JJ cancer_NN in_IN the_DT assessed_VBN benign_JJ group_NN was_VBD lower_JJR ,_, but_CC the_DT difference_NN was_VBD not_RB significant_JJ ,_, possibly_RB due_JJ to_TO the_DT small_JJ size_NN of_IN the_DT assessed_VBN benign_JJ group_NN (_( OR_NP ,_, 0.50_CD ;_: 95_CD %_NN CI_NP ,_, 0.07_CD --_: 3.55_CD )_) ._SENT Table_NP 2_CD |_SYM Likelihood_NN of_IN presentation_NN of_IN interval_NN cancer_NN following_VBG an_DT initial_JJ screen_NN ,_, and_CC of_IN detection_NN of_IN cancer_NN by_IN screening_NN at_IN the_DT second_JJ screening_NN round_NN ,_, by_IN assessment_NN status_NN Numbers_NP and_CC proportions_NNS of_IN women_NNS with_IN appointments_NNS for_IN ,_, and_CC attending_VBG ,_, the_DT second_JJ screen_NN are_VBP presented_VBN ,_, by_IN study_NN group_NN and_CC interval_NN cancer_NN status_NN ,_, in_IN Table_NP ,_, which_WDT also_RB presents_VBZ the_DT ORs_NN for_IN the_DT likelihood_NN of_IN recorded_JJ appointments_NNS and_CC reattendance_NN ._SENT Explanations_NNS for_IN a_DT lack_NN of_IN recorded_JJ reinvitation_NN appointment_NN include_VBP deletion_NN of_IN appointments_NNS cancelled_VBN in_IN advance_NN ,_, and_CC removal_NN of_IN women_NNS from_IN the_DT invitation_NN list_NN following_VBG moving_JJ house_NN ,_, bilateral_JJ mastectomy_NN or_CC death_NN ._SENT Overall_RB ,_, 90.6_CD %_NN of_IN women_NNS had_VBD recorded_VBN appointments_NNS for_IN a_DT second_JJ screen_NN within_IN 3.5_CD years_NNS ,_, and_CC 85.6_CD %_NN reattended_JJ ._SENT Compared_VBN with_IN the_DT nonassessed_JJ normal_JJ group_NN ,_, the_DT proportion_NN with_IN recorded_JJ appointments_NNS was_VBD slightly_RB lower_JJR among_IN the_DT assessed_VBN normal_JJ group_NN (_( OR_NP ,_, 0.78_CD ;_: 95_CD %_NN CI_NP ,_, 0.71_CD --_: 0.86_LS )_) and_CC was_VBD lower_JJR still_RB among_IN the_DT assessed_VBN benign_JJ group_NN (_( OR_NP ,_, 0.51_CD ;_: 95_CD %_NN CI_NP ,_, 0.41_CD --_: 0.65_LS )_) (_( see_VB Table_NP )_) ._SENT Reattendance_NP was_VBD similarly_RB slightly_RB lower_JJR among_IN women_NNS in_IN the_DT assessed_VBN normal_JJ group_NN (_( OR_NP ,_, 0.84_CD ;_: 95_CD %_NN CI_NP ,_, 0.78_CD --_: 0.92_LS )_) compared_VBN with_IN the_DT nonassessed_JJ normal_JJ group_NN ,_, and_CC was_VBD lower_JJR still_RB among_IN the_DT assessed_VBN benign_JJ group_NN (_( OR_NP ,_, 0.65_CD ;_: 95_CD %_NN CI_NP ,_, 0.52_CD --_: 0.81_CD )_) ._SENT Reattendance_NN among_IN women_NNS with_IN recorded_VBN reinvitation_NN appointments_NNS was_VBD similar_JJ in_IN all_DT groups_NNS (_( 94_CD --_: 95_CD %_NN ,_, calculated_VBN from_IN data_NNS in_IN Table_NP )_) ._SENT Table_NP 3_CD |_SYM Numbers_NP and_CC proportions_NNS of_IN cases_NNS of_IN interval_NN cancer_NN and_CC second_JJ round_NN screen-detected_JJ cancer_NN ,_, and_CC likelihood_NN of_IN presentation_NN ,_, by_IN study_NN group_NN and_CC interval_NN cancer_NN status_NN Reattendance_NP was_VBD much_RB lower_JJR among_IN women_NNS presenting_VBG with_IN interval_NN cancer_NN following_VBG the_DT first_JJ screen_NN ._SENT Combining_VBG assessed_VBN and_CC nonassessed_JJ women_NNS ,_, 90.8_CD %_NN of_IN women_NNS without_IN interval_NN cancer_NN had_VBD reinvitation_NN appointments_NNS recorded_VBD ,_, and_CC 85.8_CD %_NN actually_RB reattended_JJ ,_, whereas_IN only_RB 27.2_CD %_NN of_IN women_NNS with_IN interval_NN cancer_NN had_VBD reinvitation_NN appointments_NNS ,_, and_CC 19.2_CD %_NN reattended_VBN (_( see_VB Table_NP )_) ._SENT Among_IN the_DT 680_CD women_NNS diagnosed_VBN with_IN cancer_NN immediately_RB following_VBG first_JJ screen_NN ,_, similarly_RB low_JJ proportions_NNS with_IN reinvitation_NN appointments_NNS (_( 250_CD of_IN 680_CD women_NNS [_SYM 36.8_CD %_NN ]_SYM )_) and_CC reattending_JJ (_( 224_CD of_IN 680_CD women_NNS [_SYM 32.9_CD %_NN ]_SYM )_) were_VBD observed_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT effects_NNS of_IN the_DT study_NN group_NN on_IN pathological_JJ attributes_NNS of_IN interval_NN cancers_NNS and_CC second_JJ round_JJ screen-detected_JJ cancers_NNS are_VBP presented_VBN in_IN Table_NP ._SENT Interval_NN cancers_NNS and_CC cancers_NNS detected_VBN at_IN second_JJ screen_NN in_IN assessed_VBN women_NNS were_VBD larger_JJR compared_VBN with_IN cancers_NNS in_IN nonassessed_JJ women_NNS ,_, with_IN more_JJR measuring_NN at_IN least_JJS 20_CD mm_NN (_( OR_NP ,_, 1.59_CD ;_: 95_CD %_NN CI_NP ,_, 0.99_CD --_: 2.55_CD )_) ._SENT This_DT effect_NN reached_VBD statistical_JJ significance_NN in_IN the_DT assessed_VBN normal_JJ group_NN (_( OR_NP ,_, 1.63_CD ;_: 95_CD %_NN CI_NP ,_, 1.01_CD --_: 2.64_CD )_) ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS between_IN assessed_VBN and_CC nonassessed_JJ women_NNS in_IN risk_NN of_IN high_JJ grade_NN (_( grade_NN 3_CD )_) cancers_NNS ._SENT Compared_VBN with_IN the_DT nonassessed_JJ normal_JJ group_NN ,_, there_EX were_VBD some_DT indications_NNS of_IN fewer_JJR high_JJ grade_NN interval_NN cancers_NNS among_IN those_DT assessed_VBN (_( OR_NP ,_, 0.47_CD ;_: 95_CD %_NN CI_NP ,_, 0.17_CD --_: 1.28_LS )_) ,_, but_CC this_DT was_VBD not_RB statistically_RB significant_JJ ._SENT Cancers_NNS detected_VBN at_IN second_JJ screen_NN in_IN women_NNS who_WP were_VBD assessed_VBN at_IN first_JJ screen_NN showed_VBD some_DT indication_NN of_IN increased_VBN risk_NN of_IN positive_JJ nodes_NNS (_( OR_NP ,_, 1.51_CD ;_: 95_CD %_NN CI_NP ,_, 0.67_CD --_: 3.39_CD )_) ._SENT There_EX was_VBD a_DT non-significant_JJ increase_NN in_IN numbers_NNS of_IN advanced_JJ stage_NN (_( stage_VB 2+_JJ )_) interval_NN and_CC second_JJ round_JJ screen-detected_JJ cancers_NNS in_IN assessed_VBN women_NNS (_( OR_NP ,_, 1.32_CD ;_: 95_CD %_NN CI_NP ,_, 0.83_CD --_: 2.11_CD )_) ._SENT Interval_NN cancers_NNS in_IN the_DT assessed_VBN normal_JJ group_NN showed_VBD a_DT slightly_RB increased_VBN tendency_NN to_TO present_VB in_IN the_DT left_JJ breast_NN (_( OR_NP ,_, 1.51_CD ;_: 95_CD %_NN CI_NP ,_, 0.77_CD --_: 2.95_CD )_) ._SENT For_IN interval_NN cancers_NNS ,_, the_DT likelihood_NN of_IN a_DT cancer_NN being_VBG of_IN high_JJ prognostic_JJ risk_NN (_( group_NN 3_CD )_) was_VBD significantly_RB lower_JJR in_IN the_DT assessed_VBN normal_JJ group_NN than_IN in_IN the_DT nonassessed_JJ group_NN (_( OR_NP ,_, 0.34_CD ;_: 95_CD %_NN CI_NP ,_, 0.12_CD --_: 0.99_CD )_) ._SENT Table_NP 4_CD |_SYM Effect_NN of_IN study_NN group_NN on_IN pathological_JJ attributes_NNS of_IN interval_NN cancers_NNS and_CC second_JJ round_JJ screen-detected_JJ cancers_NNS False-positive_JJ mammography_NN is_VBZ a_DT relatively_RB frequent_JJ occurrence_NN within_IN breast_NN screening_NN programmes_NNS ._SENT It_PP was_VBD calculated_VBN that_IN ,_, during_IN 10_CD years_NNS in_IN New_NP England_NP ,_, USA_NP ,_, one-third_NN of_IN women_NNS screened_VBN by_IN mammography_NN and_CC clinical_JJ examination_NN underwent_VBD false-positive_JJ screening_NN ._SENT Last_JJ year_NN in_IN the_DT UK_NP there_RB were_VBD around_RB 11_CD unnecessary_JJ recalls_NNS for_IN every_DT cancer_NN detected_VBN within_IN the_DT National_NP Health_NP Service_NP breast_NN screening_NN programme_NN (_( 8.3_CD %_NN of_IN women_NNS assessed_VBN at_IN first_JJ screen_NN ,_, 6.7_CD cancers_NNS detected_VBN per_IN 1000_CD screened_VBD ;_: 7.6_CD %_NN false-positive_NN at_IN first_JJ mammography_NN )_) ._SENT This_DT figure_NN fell_VBD to_TO around_RB six_CD recalls_NNS for_IN every_DT cancer_NN detected_VBN at_IN repeat_NN screening_NN (_( 3.9_CD %_NN of_IN women_NNS assessed_VBN ,_, 5.5_CD cancers_NNS detected_VBN per_IN 1000_CD screened_VBD ;_: 3.4_CD %_NN false-positive_NN at_IN subsequent_JJ mammography_NN )_) ._SENT For_IN a_DT woman_NN attending_VBG all_DT five_CD screens_NNS to_TO which_WDT she_PP is_VBZ currently_RB invited_VBN ,_, assuming_VBG the_DT result_NN of_IN each_DT screening_NN is_VBZ independent_JJ of_IN any_DT previous_JJ result_NN ,_, her_PP$ cumulative_JJ probability_NN of_IN at_IN least_JJS one_CD false-positive_JJ screening_NN is_VBZ therefore_RB around_RB 19_CD %_NN {_( 1-(P_NP [_SYM No._NN false_JJ positives_NNS on_IN first_JJ screen_NN ]_SYM x_SYM P_NN [_SYM No._NN false_JJ positives_NNS on_IN subsequent_JJ screen]4_NN )_) }_) ,_, i.e._FW {_( 1-([1-0.0763_NP ]_SYM x_SYM [_SYM 1-0.0335]4_JJ )_) }_) ._SENT In_IN East_NP Anglia_NP ,_, 4.1_CD %_NN of_IN women_NNS screened_VBN in_IN the_DT first_JJ screening_NN round_NN and_CC eligible_NN for_IN a_DT second_JJ screen_NN underwent_VBD false-positive_JJ mammography_NN at_IN first_JJ screen_NN ._SENT These_DT women_NNS were_VBD more_JJR than_IN three_CD times_NNS as_IN likely_JJ as_IN nonassessed_JJ normal_JJ women_NNS to_TO present_VB with_IN an_DT interval_NN cancer_NN before_IN the_DT second_JJ screen_NN was_VBD due_JJ ,_, and_CC more_JJR than_IN twice_RB as_RB likely_JJ to_TO have_VB a_DT cancer_NN detected_VBN at_IN second_JJ screening_NN ._SENT If_IN the_DT followup_NN period_NN of_IN the_DT current_JJ study_NN had_VBD been_VBN extended_VBN beyond_IN the_DT interscreen_NN interval_NN ,_, these_DT women_NNS might_MD have_VB continued_VBN to_TO show_VB increased_VBN risk_NN of_IN cancer_NN beyond_IN the_DT due_JJ date_NN for_IN second_JJ screen_NN ._SENT The_DT rate_NN in_IN lapsed_JJ attenders_NNS who_WP were_VBD false_RB positive_JJ at_IN first_JJ screen_NN is_VBZ thus_RB also_RB likely_JJ to_TO have_VB been_VBN high_JJ ._SENT For_IN women_NNS who_WP undergo_VBP false-positive_JJ mammography_NN and_CC then_RB present_JJ with_IN cancer_NN ,_, the_DT validity_NN of_IN the_DT negative_JJ assessment_NN comes_VBZ into_IN question_NN ._SENT Among_IN women_NNS in_IN the_DT current_JJ study_NN ,_, 12.3_CD %_NN of_IN those_DT presenting_VBG with_IN interval_NN cancer_NN after_IN the_DT first_JJ screen_NN ,_, and_CC 8.6_CD %_NN of_IN those_DT with_IN cancer_NN detected_VBN at_IN second_JJ screen_NN ,_, had_VBD previously_RB been_VBN assessed_VBN compared_VBN with_IN the_DT 4.2_CD %_NN of_IN women_NNS assessed_VBN of_IN those_DT not_RB diagnosed_VBN with_IN cancer_NN ._SENT A_DT review_NN of_IN the_DT original_JJ screening_NN films_NNS of_IN women_NNS with_IN interval_NN cancers_NNS has_VBZ shown_VBN that_IN around_RB one-fifth_JJ of_IN all_DT East_JJ Anglian_JJ cases_NNS might_MD potentially_RB be_VB prevented_VBN through_IN earlier_JJR diagnosis_NN at_IN the_DT previous_JJ screening_NN ._SENT However_RB ,_, quantification_NN of_IN the_DT extent_NN to_TO which_WDT failure_NN of_IN diagnosis_NN at_IN assessment_NN has_VBZ contributed_VBN to_TO the_DT interval_NN cancer_NN rate_NN requires_VBZ detailed_JJ comparison_NN of_IN the_DT site_NN and_CC nature_NN of_IN relevant_JJ lesions_NNS at_IN assessment_NN and_CC diagnosis_NN ,_, which_WDT was_VBD beyond_IN the_DT scope_NN of_IN the_DT current_JJ study_NN ._SENT Another_DT possible_JJ explanation_NN for_IN the_DT increased_VBN risk_NN of_IN cancer_NN in_IN women_NNS following_VBG false-positive_JJ mammography_NN might_MD be_VB that_IN a_DT characteristic_NN of_IN women_NNS 's_POS breasts_NNS which_WDT makes_VBZ them_PP difficult_JJ to_TO interpret_VB mammographically_RB and_CC predisposes_VBZ them_PP to_TO the_DT risk_NN of_IN a_DT false-positive_JJ result_NN is_VBZ actually_RB itself_PP a_DT risk_NN factor_NN for_IN breast_NN cancer_NN ._SENT Such_PDT a_DT link_NN between_IN risk_NN of_IN false-positive_JJ mammography_NN and_CC risk_NN of_IN cancer_NN might_MD be_VB hormone_NN replacement_NN therapy_NN (_( HRT_NP )_) ._SENT Laya_NP et_FW al._FW in_IN 1996_CD ,_, and_CC others_NNS since_RB ,_, demonstrated_VBD that_IN current_JJ use_NN of_IN HRT_NP by_IN women_NNS aged_VBN 50+_JJ years_NNS is_VBZ associated_VBN both_CC with_IN decreased_VBN screening_NN sensitivity_NN (_( increased_VBN interval_NN cancers_NNS )_) and_CC decreased_VBN specificity_NN (_( increased_VBN false_JJ positives_NNS )_) ._SENT Furthermore_RB ,_, long-term_JJ use_NN of_IN HRT_NP has_VBZ been_VBN shown_VBN to_TO increase_VB breast_NN cancer_NN risk_NN ._SENT It_PP has_VBZ been_VBN proposed_VBN that_IN these_DT effects_NNS of_IN HRT_NP are_VBP mediated_VBN through_IN high_JJ risk_NN (_( i.e._FW dense_JJ )_) mammographic_JJ patterns_NNS ,_, which_WDT themselves_PP have_VBP been_VBN shown_VBN to_TO be_VB associated_VBN both_CC with_IN reduced_VBN screening_NN specificity_NN and_CC with_IN increased_VBN risk_NN of_IN breast_NN cancer_NN ._SENT Unfortunately_RB ,_, information_NN on_IN HRT_NP use_NN among_IN women_NNS in_IN the_DT current_JJ study_NN was_VBD not_RB available_JJ to_TO test_VB this_DT hypothesis_NN ._SENT If_IN found_VBN relevant_JJ ,_, however_RB ,_, consideration_NN of_IN a_DT woman_NN 's_POS individual_JJ risk_NN profile_NN might_MD prove_VB helpful_JJ in_IN deciding_VBG a_DT strategy_NN for_IN subsequent_JJ rescreening_NN ._SENT In_IN addition_NN to_TO being_VBG at_IN increased_VBN risk_NN of_IN cancer_NN ,_, women_NNS who_WP experienced_VBD false-positive_JJ mammography_NN were_VBD 18_CD %_NN less_RBR likely_JJ than_IN those_DT who_WP were_VBD genuinely_RB screen_NN normal_JJ to_TO reattend_VB for_IN a_DT second_JJ screening_NN ._SENT Women_NNS who_WP underwent_VBD benign_JJ biopsy_NN were_VBD even_RB less_JJR likely_JJ (_( 35_CD %_NN )_) to_TO return_VB ._SENT This_DT finding_NN was_VBD in_IN contrast_NN with_IN reports_NNS from_IN previous_JJ studies_NNS when_WRB false-positive_JJ mammography_NN either_CC had_VBD no_DT effect_NN on_IN subsequent_JJ attendance_NN or_CC ,_, alternatively_RB ,_, actually_RB increased_VBN by_IN 20_CD %_NN the_DT likelihood_NN of_IN future_JJ reattendance_NN ,_, even_RB in_IN those_DT who_WP underwent_VBD a_DT negative_JJ biopsy_NN ._SENT As_IN previously_RB suggested_VBN ,_, however_RB ,_, regional_JJ variations_NNS in_IN handling_VBG of_IN assessment_NN procedures_NNS and_CC false-positive_JJ cases_NNS may_MD explain_VB differences_NNS in_IN uptake_NN of_IN screening_NN reinvitations_NNS ._SENT Such_JJ findings_NNS suggest_VBP that_IN the_DT figures_NNS may_MD be_VB amenable_JJ to_TO improvement_NN through_IN a_DT change_NN in_IN practice_NN ._SENT The_DT reduced_VBN reattendance_NN among_IN women_NNS with_IN false-positive_JJ mammography_NN was_VBD accompanied_VBN by_IN a_DT reduced_VBN likelihood_NN of_IN reinvitation_NN appointments_NNS recorded_VBN on_IN the_DT screening_NN computer_NN system_NN ._SENT Followup_NN of_IN the_DT 85_CD assessed_VBD benign_JJ women_NNS who_WP did_VBD not_RB have_VB reinvitation_NN appointments_NNS recorded_VBN on_IN the_DT computer_NN system_NN revealed_VBD that_IN at_IN least_JJS 35_CD of_IN them_PP (_( 41_CD %_NN )_) had_VBD been_VBN offered_VBN reinvitation_NN appointments_NNS ,_, which_WDT they_PP had_VBD cancelled_VBN in_IN advance_NN ._SENT The_DT reduced_VBN reattendance_NN among_IN assessed_VBN women_NNS would_MD not_RB have_VB been_VBN apparent_JJ had_VBD the_DT analysis_NN investigated_VBD the_DT proportions_NNS of_IN women_NNS with_IN recorded_VBN reinvitation_NN appointments_NNS who_WP returned_VBD ,_, since_IN reattendance_NN among_IN those_DT with_IN recorded_JJ reinvitation_NN appointments_NNS was_VBD similarly_RB high_JJ in_IN all_DT women_NNS (_( around_RB 94_CD %_NN )_) ,_, regardless_RB of_IN assessment_NN history_NN ._SENT Furthermore_RB ,_, such_JJ analysis_NN would_MD have_VB failed_VBN to_TO reveal_VB the_DT correct_JJ magnitude_NN of_IN the_DT increased_VBN risk_NN of_IN cancer_NN among_IN women_NNS undergoing_VBG false-positive_JJ mammography_NN ,_, since_IN the_DT OR_NN for_IN an_DT interval_NN cancer_NN arising_VBG in_IN all_DT assessed_VBN women_NNS versus_CC that_IN in_IN nonassessed_JJ women_NNS was_VBD 3.19_CD (_( 95_CD %_NN CI_NP ,_, 2.34_CD --_: 4.35_CD )_) ._SENT This_DT OR_NN fell_VBD to_TO 1.21_CD (_( 95_CD %_NN CI_NP ,_, 0.49_CD --_: 2.97_LS )_) when_WRB only_RB those_DT women_NNS with_IN recorded_VBN reinvitation_NN appointments_NNS within_IN 3.5_CD years_NNS were_VBD considered_VBN (_( data_NNS not_RB shown_VBN )_) ._SENT Regardless_RB of_IN whether_IN the_DT lack_NN of_IN recorded_JJ reinvitation_NN appointments_NNS is_VBZ due_JJ to_TO an_DT active_JJ choice_NN on_IN the_DT part_NN of_IN women_NNS not_RB to_TO attend_VB or_CC due_JJ to_TO a_DT failure_NN of_IN the_DT system_NN to_TO reinvite_VB them_PP ,_, the_DT fact_NN that_IN they_PP are_VBP not_RB being_VBG rescreened_VBN yet_CC they_PP are_VBP at_IN increased_VBN risk_NN of_IN cancer_NN is_VBZ clearly_RB of_IN great_JJ concern_NN ._SENT False-positive_JJ mammography_NN ,_, leading_VBG to_TO unnecessary_JJ assessment_NN of_IN disease-free_JJ women_NNS ,_, has_VBZ associated_VBN costs_NNS ._SENT First_RB ,_, there_EX are_VBP the_DT psychological_JJ costs_NNS of_IN inconvenience_NN and_CC increased_VBN anxiety_NN in_IN women_NNS unnecessarily_RB recalled_VBD ._SENT Second_RB ,_, there_EX are_VBP the_DT direct_JJ financial_JJ costs_NNS to_TO the_DT health_NN service_NN of_IN unnecessary_JJ procedures_NNS ._SENT Third_JJ ,_, there_EX are_VBP the_DT overall_JJ costs_NNS to_TO the_DT invited_VBN population_NN of_IN the_DT reduced_VBN effectiveness_NN of_IN screening_NN ._SENT East_JJ Anglian_JJ women_NNS undergoing_VBG false-positive_JJ first_JJ mammography_NN were_VBD more_RBR likely_JJ to_TO present_VB with_IN cancer_NN and_CC less_RBR likely_JJ to_TO reattend_VB for_IN a_DT second_JJ screen_NN ._SENT The_DT impact_NN of_IN nonreattendance_NN on_IN potential_JJ subsequent_JJ mortality_NN reduction_NN is_VBZ not_RB insignificant_JJ since_IN ,_, for_IN those_DT who_WP do_VBP not_RB reattend_VB ,_, the_DT stage_NN of_IN any_DT subsequently_RB diagnosed_VBN cancers_NNS will_MD be_VB shifted_VBN from_IN earlier_RBR ,_, when_WRB detected_VBN by_IN screening_NN ,_, to_TO later_RBR ,_, when_WRB presenting_VBG symptomatically_RB in_IN lapsed_JJ attenders_NNS ._SENT For_IN women_NNS who_WP experienced_VBD false-positive_JJ mammography_NN and_CC then_RB presented_VBN with_IN an_DT interval_NN or_CC screen-detected_JJ cancer_NN ,_, the_DT current_JJ study_NN indicated_VBD that_IN these_DT cancers_NNS were_VBD more_RBR likely_JJ to_TO measure_VB 20+_JJ mm_NN and_CC to_TO be_VB of_IN a_DT higher_JJR stage_NN than_IN those_DT in_IN nonassessed_JJ women_NNS ,_, and_CC second_JJ screen-detected_JJ cancers_NNS were_VBD more_RBR likely_JJ to_TO be_VB node_NN positive_JJ ._SENT This_DT indicates_VBZ a_DT poorer_JJR prognosis_NN for_IN women_NNS who_WP presented_VBD with_IN cancer_NN having_VBG undergone_VBN false-positive_JJ mammography_NN ,_, although_IN when_WRB assessed_VBN by_IN histological_JJ subtype_NN and_CC grade_NN such_JJ cancers_NNS were_VBD apparently_RB of_IN lower_JJR prognostic_JJ risk_NN than_IN those_DT in_IN nonassessed_JJ women_NNS ._SENT The_DT reasons_NNS for_IN this_DT inconsistency_NN are_VBP unclear_JJ ._SENT The_DT current_JJ findings_NNS relate_VBP to_TO women_NNS assessed_VBN at_IN first_JJ screen_NN within_IN the_DT East_NP Anglia_NP screening_NN programme_NN ,_, carried_VBD out_RP over_IN the_DT period_NN 1989_CD --_: 1995_CD ._SENT With_IN technical_JJ improvements_NNS to_TO the_DT programme_NN and_CC women_NNS 's_POS increased_VBN familiarity_NN with_IN it_PP ,_, reduced_VBN reattendance_NN and_CC increased_VBN risk_NN of_IN cancer_NN may_MD be_VB less_RBR associated_VBN with_IN false-positive_JJ mammography_NN at_IN first_JJ screen_NN ._SENT Furthermore_RB ,_, the_DT impact_NN of_IN false-positive_JJ mammography_NN may_MD be_VB lower_JJR after_IN a_DT second_JJ or_CC subsequent_JJ screening_NN ._SENT Fewer_JJR women_NNS are_VBP assessed_VBN at_IN second_JJ and_CC subsequent_JJ screens_NNS ,_, possibly_RB due_JJ to_TO the_DT increase_NN in_IN specificity_NN associated_VBN with_IN the_DT availability_NN of_IN previous_JJ films_NNS for_IN comparison_NN ._SENT Finally_RB ,_, it_PP should_MD be_VB noted_VBN that_IN ,_, while_IN there_EX was_VBD increased_VBN risk_NN of_IN subsequent_JJ cancer_NN associated_VBN with_IN women_NNS assessed_VBN at_IN first_JJ screen_NN ,_, such_JJ women_NNS contributed_VBD only_RB a_DT modest_JJ proportion_NN of_IN all_DT interval_NN and_CC second_JJ round_JJ screen-detected_JJ cancers_NNS ._SENT False-positive_JJ mammography_NN in_IN the_DT first_JJ screening_NN round_NN in_IN East_NP Anglia_NP was_VBD associated_VBN both_CC with_IN increased_VBN risk_NN of_IN interval_NN cancers_NNS and_CC cancer_NN detected_VBN at_IN second_JJ screening_NN ,_, and_CC with_IN reduced_VBN reattendance_NN at_IN subsequent_JJ screens_NNS ._SENT If_IN these_DT associations_NNS persist_VBP within_IN the_DT screening_NN programme_NN ,_, then_RB efforts_NNS must_MD be_VB made_VBN to_TO identify_VB the_DT factors_NNS predisposing_VBG certain_JJ women_NNS to_TO false-positive_JJ mammography_NN ,_, to_TO encourage_VB continued_JJ participation_NN ,_, and_CC to_TO detect_VB any_DT subsequent_JJ cancers_NNS at_IN the_DT earliest_RBS possible_JJ opportunity_NN ._SENT CI_NN =_SYM confidence_NN interval_NN ;_: HRT_NP =_SYM hormone_NN replacement_NN therapy_NN ;_: OR_NP =_SYM odds_NN ratio_NN ._SENT 